Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis

Gibney, 2016, Predictive biomarkers for checkpoint inhibitor-based immunotherapy, Lancet Oncol, 17, e542, 10.1016/S1470-2045(16)30406-5 Hegde, 2020, Top 10 Challenges in Cancer Immunotherapy, Immunity, 52, 17, 10.1016/j.immuni.2019.12.011 Sholl, 2020, Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee, J Thorac Oncol, 15, 10.1016/j.jtho.2020.05.019 Jardim, 2021, The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker, Cancer Cell, 39, 154, 10.1016/j.ccell.2020.10.001 Valero, 2021, Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase, JAMA Oncol, 7, 739, 10.1001/jamaoncol.2020.7684 Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat Genet, 51, 202, 10.1038/s41588-018-0312-8 Fang, 2019, Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer, Clin Cancer Res, 25, 5015, 10.1158/1078-0432.CCR-19-0585 Carbone, 2017, First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493 Hellmann, 2018, Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden, N Engl J Med, 378, 2093, 10.1056/NEJMoa1801946 Zhu, 2019, Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis, Front Pharmacol, 10, 673, 10.3389/fphar.2019.00673 Kim, 2019, Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis, Cancers (Basel), 11, 1798, 10.3390/cancers11111798 Wu, 2019, The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis, Front Oncol, 9, 1161, 10.3389/fonc.2019.01161 Osipov, 2020, Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis, Clin Cancer Res, 26, 4842, 10.1158/1078-0432.CCR-20-0458 Duan, 2020, Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis, JAMA Oncol, 6, 375, 10.1001/jamaoncol.2019.5367 Page, 2020, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372, n71 Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations, Ann Intern Med, 162, 777, 10.7326/M14-2385 Tierney, 2007, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials, 8, 16, 10.1186/1745-6215-8-16 Higgins, 2016, A revised tool for assessing risk of bias in randomized trials, Cochrane Db Syst Rev, 10, 29 Herbst, 2019, Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials, Ann Oncol, 30, v916, 10.1093/annonc/mdz394.077 Rizvi, 2019, Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m)NSCLC, J Clin Oncol, 37, 9016, 10.1200/JCO.2019.37.15_suppl.9016 Gandara, 2018, Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med, 24, 1441, 10.1038/s41591-018-0134-3 Garassino, 2020, Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC, J Clin Oncol, 38, 9521, 10.1200/JCO.2020.38.15_suppl.9521 Paz-Ares, 2019, Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407, Ann Oncol, 30, v917, 10.1093/annonc/mdz394.078 Peters, 2019, Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab +/- tremelimumab vs chemotherapy, Cancer Res, 79, CT074, 10.1158/1538-7445.AM2019-CT074 Hellmann, 2019, Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer, N Engl J Med, 381, 2020, 10.1056/NEJMoa1910231 Herbst, 2021, 5-Year Survival Update From KEYNOTE-010: pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer, J Thorac Oncol, 16, 1718, 10.1016/j.jtho.2021.05.001 Herbst, 2020, Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC, N Engl J Med, 383, 1328, 10.1056/NEJMoa1917346 Paz-Ares, 2021, 98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA, J Thorac Oncol, 16, S750, 10.1016/S1556-0864(21)01940-7 Wang, 2021, FP04.02 RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC, J Thorac Oncol., 16, S950, 10.1016/j.jtho.2021.08.216 Rizvi, 2018, Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing, J Clin Oncol, 36, 633, 10.1200/JCO.2017.75.3384 Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Shim, 2020, HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients, Ann Oncol, 31, 902, 10.1016/j.annonc.2020.04.004 Hellmann, 2018, Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer, Cancer Cell, 33, 843, 10.1016/j.ccell.2018.03.018 Miao, 2018, Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors, Nat Genet, 50, 1271, 10.1038/s41588-018-0200-2 Gandara, 2018, Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med, 24, 1441, 10.1038/s41591-018-0134-3 Rizvi, 2020, Durvalumab with or without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: the MYSTIC Phase 3 Randomized Clinical Trial, JAMA Oncol, 6, 661, 10.1001/jamaoncol.2020.0237 Lieber, 2018, Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC, Cancer Immunol Res, 6 Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, 9, 34, 10.1186/s13073-017-0424-2 Fancello, 2019, Tumor mutational burden quantification from targeted gene panels: major advancements and challenges, J Immunother Cancer, 7, 183, 10.1186/s40425-019-0647-4 Klein, 2021, Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy, Cancer Cell, 39, 592, 10.1016/j.ccell.2021.04.005 Cao, 2019, High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients, Oncoimmunology, 8, 10.1080/2162402X.2019.1629258 Merino, 2020, Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project, J Immunother Cancer, 8, 10.1136/jitc-2019-000147 Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat Genet, 51, 202, 10.1038/s41588-018-0312-8 McGrail, 2021, High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types, Ann Oncol, 32, 661, 10.1016/j.annonc.2021.02.006 Kim, 2019, Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing, Eur J Cancer, 120, 65, 10.1016/j.ejca.2019.08.001 Gutierrez, 2019, KEYNOTE-495/KeyImPaCT: a randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non-small cell lung cancer (NSCLC), Ann Oncol, 30, v656, 10.1093/annonc/mdz260.111 Peng, 2020, Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma, Oncoimmunology, 9, 10.1080/2162402X.2020.1734156 Charoentong, 2017, Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade, Cell Rep, 18, 248, 10.1016/j.celrep.2016.12.019 Carbone, 2017, First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493